Tissue-resident FOLR2


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
31 03 2022
Historique:
received: 16 11 2020
revised: 08 10 2021
accepted: 15 02 2022
pubmed: 25 3 2022
medline: 19 4 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

Macrophage infiltration is a hallmark of solid cancers, and overall macrophage infiltration correlates with lower patient survival and resistance to therapy. Tumor-associated macrophages, however, are phenotypically and functionally heterogeneous. Specific subsets of tumor-associated macrophage might be endowed with distinct roles on cancer progression and antitumor immunity. Here, we identify a discrete population of FOLR2

Identifiants

pubmed: 35325594
pii: S0092-8674(22)00201-X
doi: 10.1016/j.cell.2022.02.021
pii:
doi:

Substances chimiques

FOLR2 protein, human 0
Folate Receptor 2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1189-1207.e25

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A19258
Pays : United Kingdom

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors J.H., R.N.R., E.P., and P.G. and their institutions have filed a patent related to this work.

Auteurs

Rodrigo Nalio Ramos (R)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Yoann Missolo-Koussou (Y)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Yohan Gerber-Ferder (Y)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Christian P Bromley (CP)

Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK.

Mattia Bugatti (M)

Department of Pathology, University of Brescia, Brescia 25123, Italy.

Nicolas Gonzalo Núñez (NG)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Jimena Tosello Boari (J)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Wilfrid Richer (W)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Laurie Menger (L)

PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France.

Jordan Denizeau (J)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Christine Sedlik (C)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Pamela Caudana (P)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Fiorella Kotsias (F)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Leticia L Niborski (LL)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Sophie Viel (S)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Mylène Bohec (M)

PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France.

Sonia Lameiras (S)

PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France.

Sylvain Baulande (S)

PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France.

Laëtitia Lesage (L)

PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.

André Nicolas (A)

PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.

Didier Meseure (D)

PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.

Anne Vincent-Salomon (A)

PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.

Fabien Reyal (F)

PSL University, Institut Curie Hospital, Department of Surgery, 75005 Paris, France.

Charles-Antoine Dutertre (CA)

Université Paris-Saclay, Institut Gustave Roussy, INSERM U1015, Villejuif, France.

Florent Ginhoux (F)

Université Paris-Saclay, Institut Gustave Roussy, INSERM U1015, Villejuif, France; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648, Singapore.

Lene Vimeux (L)

University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France.

Emmanuel Donnadieu (E)

University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France.

Bénédicte Buttard (B)

INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France.

Jérôme Galon (J)

INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France.

Santiago Zelenay (S)

Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK.

William Vermi (W)

PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Pierre Guermonprez (P)

Université de Paris, Centre for Inflammation Research, CNRS ERL8252, INSERM1149, Paris, France.

Eliane Piaggio (E)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.

Julie Helft (J)

PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France. Electronic address: julie.helft@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH